JPMorgan Chase & Co. Lowers QuidelOrtho (NASDAQ:QDEL) Price Target to $25.00

QuidelOrtho (NASDAQ:QDEL - Free Report) had its price objective reduced by JPMorgan Chase & Co. from $38.00 to $25.00 in a research note published on Monday morning,Benzinga reports. They currently have an underweight rating on the stock.

Other analysts have also issued reports about the company. Royal Bank of Canada dropped their price objective on QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating on the stock in a report on Thursday, February 13th. StockNews.com lowered QuidelOrtho from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. Finally, UBS Group raised their price target on shares of QuidelOrtho from $43.00 to $45.00 and gave the stock a "neutral" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $46.83.

QuidelOrtho Stock Performance

NASDAQ:QDEL traded up $0.31 during midday trading on Monday, hitting $28.09. The company's stock had a trading volume of 1,190,998 shares, compared to its average volume of 999,926. The firm has a market cap of $1.89 billion, a P/E ratio of -0.93 and a beta of 0.43. QuidelOrtho has a fifty-two week low of $23.77 and a fifty-two week high of $49.45. The firm's 50 day moving average is $33.62 and its 200-day moving average is $38.92. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 0.69.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 3.78% and a negative net margin of 72.84%. Equities analysts anticipate that QuidelOrtho will post 2.3 earnings per share for the current fiscal year.

Institutional Trading of QuidelOrtho

Large investors have recently modified their holdings of the stock. Quarry LP purchased a new stake in shares of QuidelOrtho during the 4th quarter worth $43,000. True Wealth Design LLC boosted its position in shares of QuidelOrtho by 300.7% in the 4th quarter. True Wealth Design LLC now owns 1,074 shares of the company's stock valued at $48,000 after purchasing an additional 806 shares during the period. Blue Trust Inc. boosted its holdings in shares of QuidelOrtho by 188.0% in the fourth quarter. Blue Trust Inc. now owns 1,293 shares of the company's stock valued at $58,000 after acquiring an additional 844 shares during the period. Spire Wealth Management purchased a new position in QuidelOrtho during the 4th quarter worth $74,000. Finally, KBC Group NV increased its stake in QuidelOrtho by 122.9% in the fourth quarter. KBC Group NV now owns 3,437 shares of the company's stock valued at $153,000 after purchasing an additional 1,895 shares during the period. Hedge funds and other institutional investors own 99.00% of the company's stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.